Sepsis beyond bundles: contextualising paediatric care in resource-limited settings through situational analysis. BMJ Paediatr Open. 2025 Feb 12; 9(1). View Sepsis beyond bundles: contextualising paediatric care in resource-limited settings through situational analysis. Abstract

Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers. J Cyst Fibros. 2025 Jan 22. View Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers. Abstract

Cystic Fibrosis Experience of Care Survey: Patient-Caregiver-Clinician Collaborative Design and Implementation. J Patient Exp. 2024; 11:23743735241302739. View Cystic Fibrosis Experience of Care Survey: Patient-Caregiver-Clinician Collaborative Design and Implementation. Abstract

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy. Chest. 2025 Feb; 167(2):348-361. View Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy. Abstract

Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. Front Nutr. 2024; 11:1441201. View Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. Abstract

Health care transition quadruple aim outcomes for IDD: Scoping review. Health Care Transit. 2024; 2:100067. View Health care transition quadruple aim outcomes for IDD: Scoping review. Abstract

Healthcare transition readiness of families of youth with cystic fibrosis during COVID-19: A correlational multicenter analysis. Health Care Transit. 2024; 2:100065. View Healthcare transition readiness of families of youth with cystic fibrosis during COVID-19: A correlational multicenter analysis. Abstract

Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Front Endocrinol (Lausanne). 2024; 15:1293709. View Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Abstract

De novo mutations mediate phenotypic switching in an opportunistic human lung pathogen. bioRxiv. 2024 Feb 06. View De novo mutations mediate phenotypic switching in an opportunistic human lung pathogen. Abstract

Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Diabetes Care. 2024 Jan 01; 47(1):101-108. View Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Abstract

Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities. Sci Rep. 2023 09 12; 13(1):15030. View Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities. Abstract

Development and Validation of a Respiratory-Responsive Vocal Biomarker-Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case-Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19. J Med Internet Res. 2023 04 14; 25:e44410. View Development and Validation of a Respiratory-Responsive Vocal Biomarker-Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case-Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19. Abstract

Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis. J Cyst Fibros. 2023 09; 22(5):796-803. View Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis. Abstract

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Lancet Respir Med. 2023 06; 11(6):550-562. View Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Abstract

Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1444-e1454. View Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. Abstract

The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Nutrients. 2022 Jan 12; 14(2). View The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Abstract

Issues affecting young people with asthma through the transition period to adult care. Paediatr Respir Rev. 2022 Mar; 41:30-39. View Issues affecting young people with asthma through the transition period to adult care. Abstract

Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):1026-1034. View Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. Abstract

The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022 03; 21(2):258-263. View The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. Abstract

Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 09; 18(9):1588-1592. View Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Abstract

Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol. 2022 02; 57 Suppl 1:S75-S88. View Family-building and parenting considerations for people with cystic fibrosis. Abstract

The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261. View The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. Abstract

Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123. View Men's health in the modern era of cystic fibrosis. Abstract

Integration of mental health screening and treatment into cystic fibrosis clinics: Evaluation of initial implementation in 84 programs across the United States. Pediatr Pulmonol. 2020 11; 55(11):2995-3004. View Integration of mental health screening and treatment into cystic fibrosis clinics: Evaluation of initial implementation in 84 programs across the United States. Abstract

Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the COVID-19 Pandemic. J Adolesc Health. 2020 09; 67(3):453-455. View Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the COVID-19 Pandemic. Abstract

Children's Hospitals Caring for Adults During a Pandemic: Pragmatic Considerations and Approaches. J Hosp Med. 2020 05; 15(5):311-313. View Children's Hospitals Caring for Adults During a Pandemic: Pragmatic Considerations and Approaches. Abstract

Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study. Lancet Respir Med. 2019 12; 7(12):1027-1038. View Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study. Abstract

Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Chest. 2019 06; 155(6):1226-1233. View Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Abstract

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. View VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Abstract

Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Abstract

A Pilot Study of Inspiratory Muscle Training to Improve Exercise Capacity in Patients with Fontan Physiology. Semin Thorac Cardiovasc Surg. 2018 Winter; 30(4):462-469. View A Pilot Study of Inspiratory Muscle Training to Improve Exercise Capacity in Patients with Fontan Physiology. Abstract

Overcoming barriers to a successful transition from pediatric to adult care. Pediatr Pulmonol. 2017 Nov; 52(S48):S52-S60. View Overcoming barriers to a successful transition from pediatric to adult care. Abstract

Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clin Transl Gastroenterol. 2017 Mar 16; 8(3):e81. View Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Abstract

Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. J Pediatr Gastroenterol Nutr. 2016 11; 63(5):e92-e97. View Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. Abstract

Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Abstract

Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. Abstract

Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis. PLoS One. 2015; 10(8):e0135237. View Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis. Abstract

Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. J Cyst Fibros. 2015 Jul; 14(4):526-32. View Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. Abstract

Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. Abstract

An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples. Lab Chip. 2014 Mar 21; 14(6):1087-98. View An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples. Abstract

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros. 2013 Jan; 12(1):54-9. View Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. Abstract

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18; 363(21):1991-2003. View Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. Abstract

Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View Employment experiences among adolescents and young adults with cystic fibrosis. Abstract

A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009 Dec; 8(6):418-24. View A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. Abstract

Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009 Jul; 141(1):86-90. View Sensorineural hearing loss in patients with cystic fibrosis. Abstract

Recovery of Herbaspirillum species from persons with cystic fibrosis. J Clin Microbiol. 2008 Aug; 46(8):2774-7. View Recovery of Herbaspirillum species from persons with cystic fibrosis. Abstract

Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med. 2008 Mar; 14(3):120-33. View Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Abstract

Polymerase chain reaction/denaturing gradient gel electrophoresis (PCR/DGGE): sensitivity, band pattern analysis, and methodologic optimization. Am J Dermatopathol. 1999 Dec; 21(6):547-51. View Polymerase chain reaction/denaturing gradient gel electrophoresis (PCR/DGGE): sensitivity, band pattern analysis, and methodologic optimization. Abstract

High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 1997 Feb; 280(2):576-83. View High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. Abstract

5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther. 1995 Dec; 275(3):1638-46. View 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. Abstract

Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. 1995 Jul; 105(1):51-5. View Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. Abstract

Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol. 1995 Mar; 47(3):450-7. View Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Abstract

Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar; 268(3):1403-10. View Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. Abstract